Business
Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates
Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates New analysis of data from varoglutamstat Phase 2 program for patients with lower baseline eGFR shows consistent and pronounced treatment effect, further supporting plans to advance development in stage 3b/4 DKD Compelling kidney function data from VIVIAD Phase 2b study presented in late-breaking poster session at ASN kidney week, the world’s premier nephrology meeting Successful completion of private placement supp
About this update from Vivoryon Therapeutics N.v.
[{"type":"image","alt":"Vivoryon Therapeutics N.V.","displaySize":"","headline":null,"caption":"Vivoryon Therapeutics N.V.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":96,"url":"https://media.zenfs.com/en/globenewswire.com/b42ca3f3b80b0385983aa04ad4cdc30c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Iv4MFFdTq5UwH.s30pVCjw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b42ca3f3b80b0385983aa04ad4cdc30c","width":300,"height":96}},"lazy":false},{"type":"text","content":"Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates ","length":81,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"New analysis of data from varoglutamstat Phase 2 program for patients with lower baseline eGFR shows consistent and pronounced treatment effect, further supporting plans to advance development in stage 3b/4 DKD ","length":210,"tagName":"p"}]},{"val":[{"type":"text","content":"Compelling kidney function data from VIVIAD Phase 2b study presented in late-breaking poster session at ASN kidney week, the world’s premier nephrology meeting","length":159,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":369,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Successful completion of private placement supported by existing and new shareholders raising EUR 5.1 million; extends cash runway well into Q3 2026, providing financial runway and flexibility to realize strategic partnership ","length":225,"tagName":"p"}]},{"val":[{"type":"text","content":"Management to host conference call today at 3:00 pm CET (9:00 am EST)","length":69,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":294,"olType":false},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"text","content":"Halle (Saale) / Munich, Germany, December 4, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced financial results for the nine-month period ended September 30, 2025, and provided a corporate update.","length":402,"tagName":"p"},{"type":"text","content":"“The third quarter of 2025 and year to date have been marked by continued...